ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,701.70
0.96%
S&P ASX All Technology
3,075.00
0.84%
Brent Oil
81.295
0.00%
US Dollar vs AUD
1.49858
0.00%
Bitcoin
67,615.76
-0.16%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immunocore Holdings PLC (IMCR)

  7. Immunocore Holdings PLC (IMCR) News

IMCR

Immunocore (IMCR)

Immunocore Holdings PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMCR
DateTimeSourceHeadlineSymbolCompany
01/06/202422:00GlobeNewswire Inc.Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseNASDAQ:IMCRImmunocore Holdings PLC
01/06/202406:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
01/06/202406:05GlobeNewswire Inc.Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024NASDAQ:IMCRImmunocore Holdings PLC
31/05/202406:00GlobeNewswire Inc.Immunocore to present at the Jefferies Global Healthcare ConferenceNASDAQ:IMCRImmunocore Holdings PLC
29/05/202421:00GlobeNewswire Inc.Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanomaNASDAQ:IMCRImmunocore Holdings PLC
29/05/202406:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
29/05/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
29/05/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
29/05/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
29/05/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
24/05/202406:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
08/05/202421:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
08/05/202421:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMCRImmunocore Holdings PLC
08/05/202421:00GlobeNewswire Inc.Immunocore reports first quarter financial results and provides a business updateNASDAQ:IMCRImmunocore Holdings PLC
25/04/202400:00GlobeNewswire Inc.Immunocore announces upcoming presentation and posters at ASCO 2024NASDAQ:IMCRImmunocore Holdings PLC
05/04/202407:00GlobeNewswire Inc.Immunocore to present at upcoming investor conferencesNASDAQ:IMCRImmunocore Holdings PLC
06/03/202408:30GlobeNewswire Inc.Immunocore presented two posters at CROI 2024NASDAQ:IMCRImmunocore Holdings PLC
01/03/202423:00GlobeNewswire Inc.Immunocore to present at upcoming investor conferencesNASDAQ:IMCRImmunocore Holdings PLC
29/02/202408:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
29/02/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
28/02/202423:34GlobeNewswire Inc.Immunocore reports fourth quarter and full year 2023 financial results and provides a business updateNASDAQ:IMCRImmunocore Holdings PLC
28/02/202423:33Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMCRImmunocore Holdings PLC
27/02/202410:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IMCRImmunocore Holdings PLC
22/02/202423:00GlobeNewswire Inc.Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trialNASDAQ:IMCRImmunocore Holdings PLC
22/02/202408:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
22/02/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
22/02/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
22/02/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
22/02/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
21/02/202423:00GlobeNewswire Inc.Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024NASDAQ:IMCRImmunocore Holdings PLC
 Showing the most relevant articles for your search:NASDAQ:IMCR

Your Recent History

NASDAQ
AAZPLXX
Gs Finance Corp Capped P...
LSE
BO28
Cred Ag Co 29
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved